Fitch estimates JPL's EBITDA to drop significantly in FY23 due to lower volume and narrowing of the margin to 11% (FY22 estimate: 14%).
Ligand expects 2022 royalties of $55 million to $60 million, material sales of $40 million to $50 million, and contract revenue of $52 million to $62 million.
More than 2,500 submissions are currently under review in the Food and Drug Administration's (FDA) cell and gene therapy pipeline
Key takeaways of Q3FY22 quarter & conference call highlights
Key takeaways of recent quarter & conference call highlights
Adds five years of market exclusivity on approval
NDM disorders are a group of rare, inherited neuromuscular disorders which is characterized by the inability to relax muscles following voluntary contraction
Newly formed Life Science Services business unit to offer fully integrated CDMO and Contract Testing Services
Proprietary implant-to-implant (i2i) device technology is used for communication between two implanted leadless pacemakers to regulate the heart rate
The need is to vaccinate people who have not contracted Covid-19
Subscribe To Our Newsletter & Stay Updated
